| Document Date: 2010-05-25 15:26:09
Open Document File Size: 114,03 KBShare Result on Facebook
Company Bayer / LG / Novartis / Merck and Co. / Amgen / ACS / ODA / Genzyme / Genentech / Actelion / Philips / / Continent Europe / / Country United States / / Currency USD / / / Event FDA Phase / / Facility Keck Graduate Institute of Applied Life Sciences / / IndustryTerm http / MedicalCondition Carinoid Tumors / penta-X syndrome / pseudoxanthoma elasticum / rare diseases / botulism / Acromegaly / African onchocerciasis / river blindness / Melanoma / X Syndrome / onchocerciasis / lysosomal storage disease / Renal Cell Carcinoma / Cystic Fibrosis / another disease / orphan diseases / tumors / disease / infant botulism / Hepatocellular Carcinoma / rare connective tissue disorder / rare disease / common and rare disease / similar disorders / C disease / ultra rare disease / diseases / obscure and unknown diseases / related lysosomal storage disorder / Scheindlin S. Rare diseases / Syndrome / disorders / / Organization Keck Graduate Institute of Applied Life Sciences / California Department of Health Services / FDA / / Person Boris Gites / Moses M. Two / Jessica Chang / Joseph DiMasi / Mona Chughtai / / Position Author / / Product Zavesca / Mectizan / Nexavar / Melanoma / Europe / / Technology html / http / drug development / / URL http /
SocialTag |
original Article Benefits of the Orphan Drug Act for Rare Disease Treatments Boris Gites, Mona Chughtai, Jessica Chang, and M. Ian Philips A great number of people suffer from obscure and unknown diseases for which there